What is the current Angiogenesis Therapeutic Agent market size?

The Angiogenesis Therapeutic Agent market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Angiogenesis Therapeutic Agent market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Angiogenesis Therapeutic Agent market?

Key drivers include rising cancer incidence and growing investment in angiogenesis research and development.

Which regions are leading the Angiogenesis Therapeutic Agent market?

North America and Europe are leading the market due to strong healthcare infrastructure and investment.

Who are the top companies in the Angiogenesis Therapeutic Agent market?

Top companies include Pfizer, Roche, and Merck, which are investing heavily in research and development.

What future opportunities exist in the Angiogenesis Therapeutic Agent market?

Future opportunities include emerging markets and growing demand for personalized medicine and targeted therapies.

How will technology impact the Angiogenesis Therapeutic Agent market?

Advances in technology will improve drug discovery and development, enabling more effective and targeted therapeutic agents.

What is the regulatory landscape for the Angiogenesis Therapeutic Agent market?

The regulatory landscape is complex, with stringent requirements for safety and efficacy, and ongoing monitoring of approved therapeutic agents.

What is the future outlook for the Angiogenesis Therapeutic Agent market?

The future outlook is positive, with growing demand and investment in research and development driving market growth and innovation.

Angiogenesis Therapeutic Agent Market Intelligence Report 2026 — Updated June 2026

Angiogenesis Therapeutic Agent by Application (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies), by Types (Myopic Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy, Macular Degeneration), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Angiogenesis Therapeutic Agent Market Overview

The Angiogenesis Therapeutic Agent market refers to the industry focused on developing and marketing therapeutic agents that target angiogenesis, the process of new blood vessel formation. As a crucial aspect of cancer treatment and various other diseases, the Angiogenesis Therapeutic Agent market size is expected to experience significant growth, driven by its growth outlook and market forecast. The industry expansion is anticipated to be substantial, with the global Angiogenesis Therapeutic Agent market size estimated to be around $13.3 billion in 2025, and expected to grow at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2026 to 2033. The market's scope encompasses various therapeutic agents, including anti-angiogenic and pro-angiogenic agents, which are used to treat a range of diseases, including cancer, age-related macular degeneration, and cardiovascular diseases.

Loading chart…

Key forces shaping the Angiogenesis Therapeutic Agent industry include technology shifts, such as the development of novel biomarkers and imaging technologies, regulations, such as changes in clinical trial requirements, and competitive intensity, driven by the increasing number of market players. The largest region in the Angiogenesis Therapeutic Agent market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific region. The market's growth is expected to be driven by increasing demand for effective treatments for cancer and other diseases, as well as advancements in angiogenesis research. As the market continues to evolve, it is likely to be shaped by a combination of these factors, leading to significant industry expansion and growth opportunities for market players.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences, Inc.; Eyetech Inc.; Becton, Dickinson and Company; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Novartis AG; Allergan plc; Bayer AG; Santen Pharmaceutical Co.,Ltd.; Shanghai Pharmaceuticals; Johnson & Johnson; Pfizer; Sun Pharma; Otsuka Pharmaceutical Co. Ltd; Daiichi Sankyo; ERC Labs; Medicom Health care; Implandata ophthalmic products GmbH; The Geuder Group; MORCHER GmbH; Novamedika
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Angiogenesis Therapeutic Agent market is poised for significant growth, driven by increasing demand for effective treatments of cancer and other diseases. The Angiogenesis Therapeutic Agent market size is expected to expand substantially over the forecast period, with a promising growth forecast.

Growth Drivers2 items

Advances in technology and research have led to the development of novel Angiogenesis Therapeutic Agent treatments, driving market growth and increasing the Angiogenesis Therapeutic Agent market size.

Rising prevalence of diseases such as cancer, diabetic retinopathy, and age-related macular degeneration is fueling demand for Angiogenesis Therapeutic Agent treatments, contributing to a positive growth forecast.

Restraints2 items

High development costs and stringent regulatory requirements are hindering the growth of the Angiogenesis Therapeutic Agent market, limiting the growth forecast and Angiogenesis Therapeutic Agent market size.

Side effects and risks associated with Angiogenesis Therapeutic Agent treatments are deterring some patients, thereby restraining market growth and impacting the overall Angiogenesis Therapeutic Agent market size.

Opportunities2 items

Emerging markets and increasing healthcare expenditure in developing countries are presenting new opportunities for Angiogenesis Therapeutic Agent manufacturers, driving growth forecast and expanding the Angiogenesis Therapeutic Agent market size.

Collaborations and partnerships between pharmaceutical companies and research institutions are facilitating the development of innovative Angiogenesis Therapeutic Agent treatments, contributing to a promising growth forecast and increased Angiogenesis Therapeutic Agent market size.

Challenges2 items

Intense competition among Angiogenesis Therapeutic Agent manufacturers is leading to pricing pressures, affecting profit margins and the overall Angiogenesis Therapeutic Agent market size.

Evolving regulatory landscapes and patent expirations are posing significant challenges for Angiogenesis Therapeutic Agent market players, impacting the growth forecast and Angiogenesis Therapeutic Agent market size.

Market Segmentation

Loading chart…

The Angiogenesis Therapeutic Agent market can be segmented based on Application. This segment includes various therapeutic areas where angiogenesis therapeutic agents are used, such as cancer, wound healing, and age-related macular degeneration. The application segment contributes significantly to the overall Angiogenesis Therapeutic Agent market size, with cancer being the largest application area due to the high prevalence of the disease and the growing demand for effective treatments. Understanding the Angiogenesis Therapeutic Agent segmentation is crucial for market players to identify opportunities and develop targeted strategies.

The Types segment of the Angiogenesis Therapeutic Agent market includes subtypes such as recombinant proteins, monoclonal antibodies, and small molecule inhibitors. Each subtype has its own unique characteristics, mechanisms of action, and applications. For instance, recombinant proteins are used to stimulate angiogenesis, while monoclonal antibodies are used to inhibit angiogenesis. The types segment is expected to drive the growth of the Angiogenesis Therapeutic Agent market, with monoclonal antibodies being the largest subtype due to their high efficacy and safety profiles. The market taxonomy of the Angiogenesis Therapeutic Agent market is complex, with multiple segments and subsegments, requiring a detailed analysis to understand the market dynamics.

Angiogenesis Therapeutic Agent Segmentation Breakdown9 items

Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Types

Myopic Choroidal Neovascularization

Macular Edema

Diabetic Retinopathy

Macular Degeneration

Regional Insights

Loading chart…

The Angiogenesis Therapeutic Agent market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of angiogenesis therapeutic agents, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include a strong regulatory framework, increasing demand for innovative treatments, and a high level of ecosystem maturity. Asia Pacific is driven by a large and growing patient population, increasing healthcare expenditure, and rising awareness of angiogenesis therapeutic agents. Latin America and Middle East & Africa are expected to be driven by improving infrastructure, growing demand for healthcare services, and increasing adoption of innovative treatments.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by factors such as government initiatives, increasing private investments, and a growing talent pool. The Angiogenesis Therapeutic Agent market is expected to witness significant growth in the coming years, driven by increasing demand for innovative treatments and rising awareness of angiogenesis therapeutic agents.

Competitive Landscape

The Angiogenesis Therapeutic Agent market is moderately consolidated, with a mix of global players and local/regional companies. The Angiogenesis Therapeutic Agent competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on product innovation and strategic partnerships to maintain their market position, while local/regional companies are leveraging their distribution networks and pricing strategies to compete.

Companies in the Angiogenesis Therapeutic Agent market are adopting various strategies to differentiate themselves, including technology, service model, channel strength, customization, and cost advantages. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies are focusing on strategies like M&A, partnerships, product launches, expansion, R&D, and localization. The following companies are pursuing specific strategic focuses:

Gilead Sciences, Inc. - regional expansion

Eyetech Inc. - innovation pipeline

Becton, Dickinson and Company - vertical integration

Regeneron Pharmaceuticals, Inc. - premium pricing

Genentech, Inc. - local manufacturing

Novartis AG - OEM tie-ups

Key Angiogenesis Therapeutic Agent Companies21 items

Gilead Sciences, Inc.

Eyetech Inc.

Becton, Dickinson and Company

Regeneron Pharmaceuticals, Inc.

Genentech, Inc.

Novartis AG

Allergan plc

Bayer AG

Santen Pharmaceutical Co.,Ltd.

Shanghai Pharmaceuticals

Johnson & Johnson

Pfizer

Sun Pharma

Otsuka Pharmaceutical Co. Ltd

Daiichi Sankyo

ERC Labs

Medicom Health care

Implandata ophthalmic products GmbH

The Geuder Group

MORCHER GmbH

Novamedika

Market Ecosystem

The Angiogenesis Therapeutic Agent ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of therapeutic agents, with each segment influencing the overall efficiency and effectiveness of the ecosystem. The Angiogenesis Therapeutic Agent ecosystem is characterized by a complex interplay of participants, each playing a distinct role in the value chain analysis.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing therapeutic agents

Technology providers — developing drug delivery systems

System integrators/EPCs — integrating agents with existing treatments

Distributors/channel partners — delivering agents to healthcare providers

Regulators/standards bodies — overseeing agent approval and safety

End users/buyers — healthcare providers administering therapeutic agents

The flow of value in the Angiogenesis Therapeutic Agent ecosystem is influenced by control points, such as regulatory approvals and reimbursement policies, which can impact adoption rates. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem's overall efficiency. Additionally, switching costs, partnerships, and interoperability requirements can create barriers to entry or exit, while regional differences in healthcare infrastructure and regulatory frameworks can lead to variations in the ecosystem's structure and dynamics.

Recent Industry Insights

The Angiogenesis Therapeutic Agent industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have driven innovation in the field. Notable mergers and acquisitions have also taken place, with key players expanding their portfolios to include angiogenesis therapeutic agents. Furthermore, several product and technology launches have been announced, showcasing the industry's commitment to advancing treatments for various diseases.

Additionally, regulatory changes have impacted the Angiogenesis Therapeutic Agent industry, with updates to guidelines and approvals for new therapies. A shift in consumer and enterprise trends has also been observed, with a growing focus on personalized medicine and targeted therapies. Funding rounds and expansions have supported the growth of startups and established companies, fueling research and development in the field.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Angiogenesis Therapeutic Agent market outlook. The market attractiveness is moderate, driven by the growing demand for effective treatments for cancer and other diseases. However, the competitive intensity is high, with several established players and new entrants vying for market share. The long-term outlook is positive, with the potential for significant growth driven by innovation in the field.

The innovation landscape is rapidly evolving, with advances in gene therapy and stem cell research expected to drive growth. The demand-supply balance is currently skewed, with demand outpacing supply, leading to opportunities for new players to enter the market. Key risk factors include regulatory hurdles, high development costs, and intellectual property disputes. Overall, the Angiogenesis Therapeutic Agent market offers opportunities for growth and innovation, but also poses significant challenges for players in the market.

12 items

1. Executive Summary

2. Angiogenesis Therapeutic Agent Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Angiogenesis Therapeutic Agent Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Angiogenesis Therapeutic Agent Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Angiogenesis Therapeutic Agent Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Angiogenesis Therapeutic Agent Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Angiogenesis Therapeutic Agent Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Angiogenesis Therapeutic Agent Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Angiogenesis Therapeutic Agent Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Angiogenesis Therapeutic Agent Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Angiogenesis Therapeutic Agent Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Angiogenesis Therapeutic Agent Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Angiogenesis Therapeutic Agent Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Angiogenesis Therapeutic Agent Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Angiogenesis Therapeutic Agent Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Angiogenesis Therapeutic Agent Market Competition by Key Manufacturers

9.1. Global Angiogenesis Therapeutic Agent Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Angiogenesis Therapeutic Agent: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Gilead Sciences, Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Eyetech Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Becton, Dickinson and Company

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Regeneron Pharmaceuticals, Inc.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Genentech, Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Novartis AG

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Allergan plc

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Bayer AG

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Santen Pharmaceutical Co.,Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Shanghai Pharmaceuticals

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Johnson & Johnson

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Pfizer

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Sun Pharma

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Otsuka Pharmaceutical Co. Ltd

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Daiichi Sankyo

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. ERC Labs

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Medicom Health care

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Implandata ophthalmic products GmbH

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. The Geuder Group

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. MORCHER GmbH

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Novamedika

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Angiogenesis Therapeutic Agent Market

Figure 4: Global Angiogenesis Therapeutic Agent Market: Drivers

Figure 5: Global Angiogenesis Therapeutic Agent Market: Challenges

Figure 6: Global Angiogenesis Therapeutic Agent Market: Trends

Figure 7: Global Angiogenesis Therapeutic Agent Market: Opportunity

Figure 8: Global Angiogenesis Therapeutic Agent Market: Restraint

Figure 9: Global Angiogenesis Therapeutic Agent Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Angiogenesis Therapeutic Agent Market Value (USD Million) By Region

Figure 19: Global Angiogenesis Therapeutic Agent Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Angiogenesis Therapeutic Agent Market Value (USD Million) By Region

Figure 27: Global Angiogenesis Therapeutic Agent Market Share (%) By: Regions (2032)

Figure 28: Global Angiogenesis Therapeutic Agent Market Volume (K) By Region

Figure 29: Global Angiogenesis Therapeutic Agent Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Angiogenesis Therapeutic Agent Market Value (USD Million) By Region

Figure 37: Global Angiogenesis Therapeutic Agent Market Share (%) By: Regions (2032)

Figure 38: Global Angiogenesis Therapeutic Agent Market Volume (K) By Region

Figure 39: Global Angiogenesis Therapeutic Agent Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

137 items

Table 1: Market Segmentation Analysis

Table 2: Global Angiogenesis Therapeutic Agent Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Angiogenesis Therapeutic Agent Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Angiogenesis Therapeutic Agent Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Angiogenesis Therapeutic Agent Market Value (USD Million) By Region

Table 14: Global Angiogenesis Therapeutic Agent Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Angiogenesis Therapeutic Agent Market Volume (K) By Region

Table 31: Global Angiogenesis Therapeutic Agent Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Angiogenesis Therapeutic Agent Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Angiogenesis Therapeutic Agent Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Angiogenesis Therapeutic Agent Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Gilead Sciences, Inc. Basic Information And Sales Area

Table 52: Gilead Sciences, Inc.. Products Portfolio

Table 53: Eyetech Inc. Basic Information And Sales Area

Table 54: Eyetech Inc.. Products Portfolio

Table 55: Becton, Dickinson and Company Basic Information And Sales Area

Table 56: Becton, Dickinson and Company. Products Portfolio

Table 57: Regeneron Pharmaceuticals, Inc. Basic Information And Sales Area

Table 58: Regeneron Pharmaceuticals, Inc.. Products Portfolio

Table 59: Genentech, Inc. Basic Information And Sales Area

Table 60: Genentech, Inc.. Products Portfolio

Table 61: Novartis AG Basic Information And Sales Area

Table 62: Novartis AG. Products Portfolio

Table 63: Allergan plc Basic Information And Sales Area

Table 64: Allergan plc. Products Portfolio

Table 65: Bayer AG Basic Information And Sales Area

Table 66: Bayer AG. Products Portfolio

Table 67: Santen Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 68: Santen Pharmaceutical Co.,Ltd.. Products Portfolio

Table 69: Shanghai Pharmaceuticals Basic Information And Sales Area

Table 70: Shanghai Pharmaceuticals. Products Portfolio

Table 71: Johnson & Johnson Basic Information And Sales Area

Table 72: Johnson & Johnson. Products Portfolio

Table 73: Pfizer Basic Information And Sales Area

Table 74: Pfizer. Products Portfolio

Table 75: Sun Pharma Basic Information And Sales Area

Table 76: Sun Pharma. Products Portfolio

Table 77: Otsuka Pharmaceutical Co. Ltd Basic Information And Sales Area

Table 78: Otsuka Pharmaceutical Co. Ltd. Products Portfolio

Table 79: Daiichi Sankyo Basic Information And Sales Area

Table 80: Daiichi Sankyo. Products Portfolio

Table 81: ERC Labs Basic Information And Sales Area

Table 82: ERC Labs. Products Portfolio

Table 83: Medicom Health care Basic Information And Sales Area

Table 84: Medicom Health care. Products Portfolio

Table 85: Implandata ophthalmic products GmbH Basic Information And Sales Area

Table 86: Implandata ophthalmic products GmbH. Products Portfolio

Table 87: The Geuder Group Basic Information And Sales Area

Table 88: The Geuder Group. Products Portfolio

Table 89: MORCHER GmbH Basic Information And Sales Area

Table 90: MORCHER GmbH. Products Portfolio

Table 91: Novamedika Basic Information And Sales Area

Table 92: Novamedika. Products Portfolio

Table 93: Global Market Value (USD Million) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Market Value (USD Million) (2025-2032) By Types

Table 96: Global Market Share (%) By Types (2032)

Table 97: Global Market Volume (K) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Market Volume (K) (2025-2032) By Types

Table 100: Global Market Share (%) By Types (2032)

Table 101: Global Angiogenesis Therapeutic Agent Market Value (USD Million) By Region

Table 102: Global Angiogenesis Therapeutic Agent Market Share (%) By Region (2025-2032)

Table 103: North America Market Value (USD Million) (2025-2032) By Country

Table 104: North America Market Value (USD Million) (2025-2032) By Application

Table 105: North America Market Value (USD Million) (2025-2032) By Types

Table 106: Europe Market Value (USD Million) (2025-2032) By Country

Table 107: Europe Market Value (USD Million) (2025-2032) By Application

Table 108: Europe Market Value (USD Million) (2025-2032) By Types

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 110: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 111: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 112: South America Market Value (USD Million) (2025-2032) By Country

Table 113: South America Market Value (USD Million) (2025-2032) By Application

Table 114: South America Market Value (USD Million) (2025-2032) By Types

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 116: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 117: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 118: Global Angiogenesis Therapeutic Agent Market Volume (K) By Region

Table 119: Global Angiogenesis Therapeutic Agent Market Share (%) By Region (2025-2032)

Table 120: North America Market Volume (K) (2025-2032) By Country

Table 121: North America Market Volume (K) (2025-2032) By Application

Table 122: North America Market Volume (K) (2025-2032) By Types

Table 123: Europe Market Volume (K) (2025-2032) By Country

Table 124: Europe Market Volume (K) (2025-2032) By Application

Table 125: Europe Market Volume (K) (2025-2032) By Types

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 127: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 128: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 129: South America Market Volume (K) (2025-2032) By Country

Table 130: South America Market Volume (K) (2025-2032) By Application

Table 131: South America Market Volume (K) (2025-2032) By Types

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 133: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 134: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 135: Research Programs/Design For This Report

Table 136: Key Data Information From Secondary Sources

Table 137: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Angiogenesis Therapeutic Agent Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences, Inc.; Eyetech Inc.; Becton, Dickinson and Company; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Novartis AG; Allergan plc; Bayer AG; Santen Pharmaceutical Co.,Ltd.; Shanghai Pharmaceuticals; Johnson & Johnson; Pfizer; Sun Pharma; Otsuka Pharmaceutical Co. Ltd; Daiichi Sankyo; ERC Labs; Medicom Health care; Implandata ophthalmic products GmbH; The Geuder Group; MORCHER GmbH; Novamedika
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Intense competition among Angiogenesis Therapeutic Agent manufacturers is leading to pricing pressures, affecting profit margins and the overall Angiogenesis Therapeutic Agent market size.

Market Segmentation

Loading chart…

Angiogenesis Therapeutic Agent Segmentation Breakdown9 items

Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Types

Myopic Choroidal Neovascularization

Macular Edema

Diabetic Retinopathy

Macular Degeneration

Regional Insights

Loading chart…

Competitive Landscape

Gilead Sciences, Inc. - regional expansion

Eyetech Inc. - innovation pipeline

Becton, Dickinson and Company - vertical integration

Regeneron Pharmaceuticals, Inc. - premium pricing

Genentech, Inc. - local manufacturing

Novartis AG - OEM tie-ups

Key Angiogenesis Therapeutic Agent Companies21 items

Gilead Sciences, Inc.

Eyetech Inc.

Becton, Dickinson and Company

Regeneron Pharmaceuticals, Inc.

Genentech, Inc.

Novartis AG

Allergan plc

Bayer AG

Santen Pharmaceutical Co.,Ltd.

Shanghai Pharmaceuticals

Johnson & Johnson

Pfizer

Sun Pharma

Otsuka Pharmaceutical Co. Ltd

Daiichi Sankyo

ERC Labs

Medicom Health care

Implandata ophthalmic products GmbH

The Geuder Group

MORCHER GmbH

Novamedika

Market Ecosystem

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing therapeutic agents

Technology providers — developing drug delivery systems

System integrators/EPCs — integrating agents with existing treatments

Distributors/channel partners — delivering agents to healthcare providers

Regulators/standards bodies — overseeing agent approval and safety

End users/buyers — healthcare providers administering therapeutic agents

Recent Industry Insights

Analyst Overview

Table of Contents